Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.

[1]  P Michael Ho,et al.  Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. , 2008, JAMA.

[2]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[3]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[4]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[5]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[6]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[7]  Jeroen J. Bax,et al.  Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. , 2007, Journal of the American College of Cardiology.

[8]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[9]  Anthony A Bavry,et al.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. , 2006, The American journal of medicine.

[10]  F. Burzotta,et al.  A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. , 2006, European heart journal.

[11]  G. Montalescot,et al.  Premature withdrawal and alternative therapies to dual oral antiplatelet therapy , 2006 .

[12]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[13]  Harlan M. Krumholz,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.

[14]  L. Fleisher,et al.  Coronary artery stenting and non-cardiac surgery--a prospective outcome study. , 2006, British journal of anaesthesia.

[15]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[16]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[17]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[18]  M. Pfeffer,et al.  Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial , 2005, The Lancet.

[19]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[20]  G. Montalescot,et al.  Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.

[21]  Antonio Colombo,et al.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.

[22]  J. Golmard,et al.  Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes , 2004, Circulation.

[23]  S. Yusuf,et al.  Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes , 2003, Circulation.

[24]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[25]  R. Califf,et al.  Patient-reported frequency of taking aspirin in a population with coronary artery disease. , 2002, The American journal of cardiology.

[26]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[27]  A. Raizner,et al.  Catastrophic outcomes of noncardiac surgery soon after coronary stenting. , 2000, Journal of the American College of Cardiology.

[28]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[29]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[30]  D. Atar,et al.  Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. , 2007, Thrombosis research.

[31]  B. Gersh.  Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical TrialsBavry AA, Kumbhani DJ, Helton TJ, et al (Cleveland Clinic Found, Ohio; Univ of Pennsylvania, Philadelphia): AM J Med 119:1056–1061, 2006§ , 2007 .

[32]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[33]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .